CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares Sold by Wellington Shields & Co. LLC

Wellington Shields & Co. LLC decreased its position in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 30.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 30,091 shares of the biotechnology company’s stock after selling 13,000 shares during the quarter. Wellington Shields & Co. LLC owned approximately 0.19% of CASI Pharmaceuticals worth $85,000 as of its most recent filing with the SEC.

CASI Pharmaceuticals Stock Performance

NASDAQ CASI opened at $2.20 on Friday. The company has a quick ratio of 2.32, a current ratio of 3.20 and a debt-to-equity ratio of 1.38. CASI Pharmaceuticals, Inc. has a 52-week low of $2.04 and a 52-week high of $7.67. The business’s 50-day moving average price is $2.49 and its 200 day moving average price is $4.19. The firm has a market cap of $34.15 million, a P/E ratio of -0.99 and a beta of 0.41.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on CASI Pharmaceuticals in a report on Tuesday, March 11th. They set a “hold” rating on the stock.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.